Camlin Fine Sciences (532834) Aperçu de l'action
Camlin Fine Sciences Limited, avec ses filiales, se consacre à la recherche, au développement, à la fabrication et à la commercialisation de produits chimiques spécialisés, d'ingrédients et de mélanges d'additifs en Inde et dans le monde entier. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 5/6 |
| Croissance future | 4/6 |
| Performances passées | 0/6 |
| Santé financière | 3/6 |
| Dividendes | 0/6 |
Récompenses
Analyse des risques
532834 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Camlin Fine Sciences Limited Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | ₹106.10 |
| Plus haut sur 52 semaines | ₹234.00 |
| Plus bas sur 52 semaines | ₹96.30 |
| Bêta | 0.68 |
| Variation sur 1 mois | -14.47% |
| Variation sur 3 mois | -13.42% |
| Variation sur 1 an | -49.46% |
| Variation sur 3 ans | -31.10% |
| Variation sur 5 ans | -38.06% |
| Évolution depuis l'introduction en bourse | 1,148.24% |
Nouvelles et mises à jour récentes
Mise à jour du récit • Aug 17
532834: Higher Profitability Assumptions And New Global CFO Role Will Drive Upside
Analysts have trimmed their price target on Camlin Fine Sciences from ₹165.0 to ₹140.0, citing updated assumptions around revenue growth, profit margins, and future P/E expectations. What’s in the News for Camlin Fine Sciences Board meeting scheduled on May 26, 2026, to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, and to finalize details for the 33rd Annual General Meeting.
Mise à jour du récit • Jul 21
532834: Future Margin Assumptions Will Support Bullish Re Rating Potential
Analysts have reduced the price target for Camlin Fine Sciences from ₹290 to ₹190, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E expectations. What's in the News Camlin Fine Sciences has scheduled a board meeting on May 26, 2026, at 13:30 IST to consider and approve the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.Mise à jour du récit • Jul 07
532834: Future Profit Margins And New Global CFO Role Will Drive Upside
Analysts have trimmed their price target for Camlin Fine Sciences from ₹190.00 to ₹165.00, reflecting updated assumptions that combine a lower revenue growth outlook with higher expected profit margins and a reduced future P/E multiple. What's in the News for Camlin Fine Sciences Camlin Fine Sciences plans to re-designate current CFO Mr. Santosh Parab as President, Strategy and Global CFO, effective August 18, 2026, following approval at the AGM scheduled for August 11, 2026.Recent updates
Mise à jour du récit • Aug 17
532834: Higher Profitability Assumptions And New Global CFO Role Will Drive Upside
Analysts have trimmed their price target on Camlin Fine Sciences from ₹165.0 to ₹140.0, citing updated assumptions around revenue growth, profit margins, and future P/E expectations. What’s in the News for Camlin Fine Sciences Board meeting scheduled on May 26, 2026, to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, and to finalize details for the 33rd Annual General Meeting.Mise à jour du récit • Jul 21
532834: Future Margin Assumptions Will Support Bullish Re Rating Potential
Analysts have reduced the price target for Camlin Fine Sciences from ₹290 to ₹190, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E expectations. What's in the News Camlin Fine Sciences has scheduled a board meeting on May 26, 2026, at 13:30 IST to consider and approve the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.Mise à jour du récit • Jul 07
532834: Future Profit Margins And New Global CFO Role Will Drive Upside
Analysts have trimmed their price target for Camlin Fine Sciences from ₹190.00 to ₹165.00, reflecting updated assumptions that combine a lower revenue growth outlook with higher expected profit margins and a reduced future P/E multiple. What's in the News for Camlin Fine Sciences Camlin Fine Sciences plans to re-designate current CFO Mr. Santosh Parab as President, Strategy and Global CFO, effective August 18, 2026, following approval at the AGM scheduled for August 11, 2026.
Mise à jour du récit • Jun 23
532834: Capital Structure Changes Will Support Bullish Outlook Despite CFO Role Shift
Analysts have kept their fair value estimate for Camlin Fine Sciences steady at ₹177.5, with only marginal tweaks to inputs such as the discount rate, revenue growth, profit margin and future P/E assumptions guiding the unchanged price target. What's in the News Camlin Fine Sciences has scheduled a Board meeting on May 26, 2026 to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, and to approve the 33rd AGM to be held on August 11, 2026, along with other business matters, according to a Board meeting notice.Mise à jour du récit • Jun 06
532834: Upcoming Capital Decisions Will Support Bullish Outlook Despite Leadership Restructuring
Analysts have trimmed the price target on Camlin Fine Sciences from ₹182.5 to ₹177.5, citing updated assumptions on discount rate, revenue growth, profit margin and future P/E that collectively point to a slightly lower fair value estimate. What's in the News Board meeting scheduled for May 26, 2026, to review and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, and to finalize details for the 33rd AGM on August 11, 2026.Mise à jour du récit • May 22
532834: Upcoming Capital Decisions Will Support Bullish Outlook With Stable Assumptions
Analysts have kept the price target for Camlin Fine Sciences steady at ₹182.5, with the slight tweaks in discount rate and forward P/E mainly fine tuning their valuation framework rather than signaling a major shift in outlook. What's in the News Board meeting scheduled on May 26, 2026 to consider and approve the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026 (Key Developments).Mise à jour du récit • Apr 26
532834: Upcoming Meetings Will Support Bullish Outlook With Stable Forward Assumptions
Analysts have left the Camlin Fine Sciences price target unchanged at ₹182.5, explaining that a slightly lower discount rate and marginally higher profit margin assumptions are balanced by a modestly lower future P/E input. What's in the News Special and Extraordinary Shareholders Meeting scheduled via postal ballot in India on May 7, 2026, indicating upcoming shareholder decisions that may affect the company structure or capital plans (Key Developments).Mise à jour du récit • Apr 11
532834: Upcoming Meetings Will Support Confident Outlook Despite Revised Forecast Assumptions
Analysts have trimmed their price target on Camlin Fine Sciences from ₹235 to ₹182.5. This reflects updated assumptions around fair value, revenue growth, profit margins and future P/E expectations. What's in the News Board meeting scheduled for Feb 13, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (Key Developments).Mise à jour du récit • Mar 25
532834: Upcoming Results Meeting Will Reinforce Steady Assumptions Supporting Upside Potential
Analysts have kept the fair value estimate for Camlin Fine Sciences steady at ₹235, with only minor tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E, resulting in a largely unchanged price target narrative. What's in the News Board meeting scheduled on February 13, 2026 to consider and approve the unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (company filing).Mise à jour du récit • Mar 10
532834: Scheduled Results Review Will Confirm Steady Assumptions Supporting Upside Potential
Analysts have kept their fair value estimate for Camlin Fine Sciences steady at ₹235, citing largely unchanged assumptions around revenue growth, profit margins and future P/E, with only minor tweaks to the discount rate and valuation inputs. What's in the News Board meeting scheduled for February 13, 2026, to review and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (company filing).Mise à jour du récit • Feb 24
532834: Upcoming Results Review Will Support Long Term Upside Potential
Analysts have adjusted their fair value estimate for Camlin Fine Sciences from ₹240 to ₹235, reflecting updated views on the discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News A board meeting is scheduled for February 13, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (company filing).Mise à jour du récit • Feb 09
532834: Upcoming Board And Director Decisions Will Support Long Term Upside
Analysts have maintained their fair value estimate for Camlin Fine Sciences at ₹240.00, with the small adjustments in discount rate and future P/E assumptions reflecting updated views on risk and valuation drivers rather than a change in the headline price target. What's in the News Board meeting scheduled for February 13, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Key Developments).Mise à jour du récit • Jan 25
532834: Director Reappointment And Steady Assumptions Will Support Long Term Upside
Analysts have kept their fair value estimate for Camlin Fine Sciences steady at ₹240.0 per share, with the unchanged target reflecting consistent assumptions on revenue growth, profit margin and future P/E, alongside a slightly updated discount rate input. What's in the News A board meeting is scheduled for Nov 10, 2025, to consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ended Sep 30, 2025, and to discuss other matters (Key Developments).Mise à jour du récit • Jan 11
532834: Governance Continuity And Stable Assumptions Will Support Long Term Upside
Analysts have kept their price target for Camlin Fine Sciences steady at ₹240.00. This reflects updated assumptions around a slightly higher discount rate and fine-tuned estimates for revenue growth, profit margin and future P/E, without a clear tilt in either a more optimistic or more cautious direction.Mise à jour du récit • Dec 24
532834: Share Swap And Governance Stability Will Drive Long Term Returns
Analysts have maintained their price target for Camlin Fine Sciences at ₹240.00, with only marginal tweaks to the underlying model inputs. This reflects steady confidence in the company’s growth and profitability trajectory.Mise à jour du récit • Dec 10
532834: Share Swap Acquisition Will Drive Long Term Returns
Analysts have modestly maintained their outlook on Camlin Fine Sciences, keeping the price target broadly unchanged near ₹240, as small tweaks to the discount rate and forward earnings assumptions continue to support a steady long term growth narrative. What's in the News Board meeting scheduled for November 10, 2025, to approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, and to consider the reappointment of Mahabaleshwar Palekar as a non executive independent director (Key Developments).Mise à jour du récit • Nov 26
532834: Share Swap Acquisition And Margin Expansion Will Drive Future Returns
Analysts have lowered their price target for Camlin Fine Sciences from ₹270 to ₹240. They cite updated estimates that reflect improved profit margins and revenue growth, along with a reduced valuation multiple.Mise à jour du récit • Nov 11
532834: Acquisition Plan Will Drive Shareholder Value Despite Margin Pressure
Analysts have revised their price target for Camlin Fine Sciences downward from ₹295 to ₹270. They cited lower expected profit margins, even though revenue growth is projected to be stronger.Nouveau récit • Sep 04
Tariff Benefits And Safety Trends Will Boost US And Europe
Key Takeaways Plant restarts and easing exceptional expenses are set to improve margins, with structural growth driven by global demand for compliant, high-quality food additives. Favorable trade barriers and China+1 supply diversification position Camlin Fine Sciences for market share gains, margin expansion, and reduced dependence on legacy products.Rendement pour les actionnaires
| 532834 | IN Chemicals | IN Marché | |
|---|---|---|---|
| 7D | -1.8% | 0.004% | -0.7% |
| 1Y | -49.5% | -0.1% | 2.0% |
Rendement vs Industrie: 532834 a sous-performé le secteur Indian Chemicals qui a rapporté -0.1 % au cours de l'année écoulée.
Rendement vs marché: 532834 a sous-performé le marché Indian qui a rapporté 2 % au cours de l'année écoulée.
Volatilité des prix
| 532834 volatility | |
|---|---|
| 532834 Average Weekly Movement | 8.6% |
| Chemicals Industry Average Movement | 5.9% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 3.6% |
Cours de l'action stable: Le cours de l'action de 532834 a été volatil au cours des 3 derniers mois par rapport au marché Indian.
Volatilité au fil du temps: La volatilité hebdomadaire de 532834 ( 9% ) est restée stable au cours de l'année écoulée, mais reste supérieure à 75 % des actions de Indian.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1931 | 674 | Ashish Dandekar | www.camlinfs.com |
Camlin Fine Sciences Limited, avec ses filiales, se consacre à la recherche, au développement, à la fabrication et à la commercialisation de produits chimiques spécialisés, d'ingrédients et de mélanges d'additifs en Inde et dans le monde. L'entreprise propose des solutions de conservation, qui comprennent des antioxydants, dont le butylhydroxytoluène et le palmitate d'ascorbyle, ainsi que des émulsifiants, des inhibiteurs de moisissures, des agents antibactériens, des liants de toxines, des liants de granulés, des désinfectants, des énergisants, des conservateurs, des agents épaississants et des stimulateurs de croissance, ainsi que des antioxydants d'origine végétale, tels que le mélange de tocophérols, l'extrait de thé vert et l'extrait de romarin, qui sont utilisés pour améliorer la durée de conservation sous les marques Xtendra et NaSure. Elle fournit également des ingrédients aromatiques, notamment de la vanilline et de l'éthylvanilline, des produits de santé et de bien-être et des produits chimiques de performance, tels que l'hydroquinone et le catéchol.
Camlin Fine Sciences Limited Résumé des fondamentaux
| 532834 statistiques fondamentales | |
|---|---|
| Capitalisation boursière | ₹21.06b |
| Bénéfices(TTM) | -₹548.94m |
| Recettes(TTM) | ₹18.35b |
1.1x
Ratio P/S-37.1x
Ratio P/ELe site 532834 est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| 532834 compte de résultat (TTM) | |
|---|---|
| Recettes | ₹18.35b |
| Coût des recettes | ₹10.36b |
| Marge brute | ₹8.00b |
| Autres dépenses | ₹8.55b |
| Les revenus | -₹548.94m |
Derniers bénéfices déclarés
Jun 30, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | -2.86 |
| Marge brute | 43.58% |
| Marge bénéficiaire nette | -2.99% |
| Ratio dettes/capitaux propres | 72.0% |
Quelles ont été les performances à long terme de 532834?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/08/19 16:14 |
| Cours de l'action en fin de journée | 2026/08/19 00:00 |
| Les revenus | 2026/06/30 |
| Revenus annuels | 2026/03/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Camlin Fine Sciences Limited est couverte par 9 analystes. 2 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Ankur Periwal | Axis Capital Limited |
| Abhishek Navalgund | Centrum Broking Limited |
| Satish Kumar | CGS International |